Genmab stops certain oncology programmes and cuts staff
This article was originally published in Scrip
Executive Summary
Genmab is cutting 101 jobs and dropping some of its clinical programmes to concentrate on developing fewer but "highly potential" anticancers. It initiated a portfolio review earlier this year to identify priority R&D areas as it moves towards becoming a commercial organisation, it says.